Announced
Completed
Synopsis
Verily, Alphabet Inc.'s research organization devoted to the study of life sciences, acquired a stake in DexCom, a leader in continuous glucose monitoring, for $550m. “Our collaboration remains on track to deliver our next generation CGM platform by the end of 2020,” said Kevin Sayer, Chairman, President and Chief Executive Officer of Dexcom. “This agreement aligns Dexcom’s and Verily’s mutual interests in bringing Dexcom CGM technology to a broader diabetes population.”
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.